VistaGen Therapeutics is developing innovative medicine for depression and diseases and conditions involving the central nervous system (CNS). The company’s AV-101 is a new generation orally available anti-depressant candidate entering phase 2 clinical development. Based on preclinical studies, AV-101 may also have potential as a treatment for other CNS-related conditions and neurodegenerative diseases. VistaGen is also leveraging its proprietary pluripotent stem cell technology and clinically predictive bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, for drug rescue applications.  For more information visit the company’s website at: www.vistagen.com